Session » (0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0529

Anti-PeptidylArginine Deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 0528

Apolipoprotein A1 and B Levels Indicate Specific Lipid Changes In Early Treatment Naïve Psoriatic Arthritis and Correlate With 1-year Disease Activity

10:30AM-12:30PM: Abstract Number: 0548

Artificial Intelligence in Axial Spondyloarthritis Diagnosis: Integrating Structural and Inflammatory Lesionsfrom Sacrum MRI

10:30AM-12:30PM: Abstract Number: 0536

Can achieving sustained low disease activity through treat-to-target management arrest enthesiophyte progression in psoriatic arthritis? A two-year prospective study using high resolution peripheral quantitative computed tomography

10:30AM-12:30PM: Abstract Number: 0550

Clinical and Genetic Factors Associated with Anti-TNF Therapy Initiation in Radiographic Axial Spondyloarthritis: A 15-Year Observational Study

10:30AM-12:30PM: Abstract Number: 0535

Comparing Perspectives of Physician-Assessed and Self-Reported Inflammatory Back Pain: Insights from the SHERPAS Cohort

10:30AM-12:30PM: Abstract Number: 0525

Cost-of-Illness Among Newly Diagnosed Patients with Psoriatic Arthritis in Sweden

10:30AM-12:30PM: Abstract Number: 0547

Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0538

Development of an Artificial Intelligence Tool for Lesion Detection in Axial Spondyloarthritis patients with Active Sacroiliitis on Magnetic Resonance Imaging

10:30AM-12:30PM: Abstract Number: 0551

Enthesitis Beyond the Surface: Ultrasonographic Unmasking of Preclinical Psoriatic Arthritis in Cutaneous Psoriasis

10:30AM-12:30PM: Abstract Number: 0530

Evaluating ChatGPT’s Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties

10:30AM-12:30PM: Abstract Number: 0531

Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach

10:30AM-12:30PM: Abstract Number: 0527

Gaps In Documentation Of Psoriatic Arthritis Domains In General Rheumatologic Practices Compared To Rheumatology-Dermatology Combined Clinics

10:30AM-12:30PM: Abstract Number: 0532

Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis

10:30AM-12:30PM: Abstract Number: 0549

High Prevalence of Obstructive Sleep Apnea in Psoriatic Arthritis: A Polysomnography-Based Cross-Sectional Study

10:30AM-12:30PM: Abstract Number: 0537

HLA-B27 and Axial Involvement as Independent Risk Factors for Uveitis in Spondyloarthritis: New Insights from a 15-Year Real-Life Study

10:30AM-12:30PM: Abstract Number: 0526

Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis

10:30AM-12:30PM: Abstract Number: 0541

Inflammatory Back Pain Is Not Associated With HLA-B27 Positivity or CRP Levels in a Nationally Representative U.S. Population

10:30AM-12:30PM: Abstract Number: 0540

Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease

10:30AM-12:30PM: Abstract Number: 0553

Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain

10:30AM-12:30PM: Abstract Number: 0546

Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study

10:30AM-12:30PM: Abstract Number: 0544

Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort

10:30AM-12:30PM: Abstract Number: 0534

Prevalence and Impact of Fibromyalgia on Disease Outcomes and Treatment in Axial Spondyloarthritis: 10-year Follow-up Data From the DESIR Cohort

10:30AM-12:30PM: Abstract Number: 0524

Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors

10:30AM-12:30PM: Abstract Number: 0552

Radiographic Sacroiliitis Progression in Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 0533

Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission

10:30AM-12:30PM: Abstract Number: 0523

SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement

10:30AM-12:30PM: Abstract Number: 0545

Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis

10:30AM-12:30PM: Abstract Number: 0522

The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 0542

Transition from Psoriasis to Psoriatic Arthritis: Does Family History Influence the Time to Onset of Arthritis in Psoriasis Patients?

10:30AM-12:30PM: Abstract Number: 0543

Unveiling Sacroiliac Joint Involvement in Psoriatic Arthritis: MRI, Radiographic, and Clinical Insights from 581 European Routine Care Patients

10:30AM-12:30PM: Abstract Number: 0539

Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].